CMB Leads $65M Series C Round In Chinese Biotech Firm Biocytogen

DNA

CMB International Capital Corporation Ltd, a wholly-owned subsidiary of China Merchants Bank, has led a RMB410 million (US$65 million) series C round in Beijing Biocytogen Co., Ltd., a gene targeted animal model and service supplier.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets

LEAVE A REPLY